A Self-Assembled Platform Based on Branched DNA for sgRNA/Cas9/Antisense Delivery

J Am Chem Soc. 2019 Dec 4;141(48):19032-19037. doi: 10.1021/jacs.9b09043. Epub 2019 Nov 20.

Abstract

Precisely assembled DNA nanostructures are promising candidates for the delivery of biomolecule-based therapeutics. Herein, we introduce a facile strategy for the construction of a branched DNA-based nanoplatform for codelivery of gene editing (sgRNA/Cas9, targeting DNA in the nucleus) and gene silencing (antisense, targeting mRNA in the cytoplasm) components for synergistic tumor therapy in vitro and in vivo. In our design, the branched DNA structure can efficiently load a sgRNA/Cas9/antisense complex targeting a tumor-associated gene, PLK1, through DNA self-assembly. With the incorporation of an active targeting aptamer and an endosomal escape peptide by host-guest interaction, the biocompatible DNA nanoplatform demonstrates efficient inhibition of tumor growth without apparent systemic toxicity. This multifunctional DNA nanocarrier provides a new strategy for the development of gene therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms / genetics
  • Breast Neoplasms / therapy*
  • CRISPR-Cas Systems*
  • Cell Cycle Proteins / genetics
  • DNA / chemistry*
  • Female
  • Gene Editing / methods*
  • Genetic Therapy / methods
  • Humans
  • MCF-7 Cells
  • Mice
  • Mice, Inbred BALB C
  • Nanostructures / chemistry
  • Polo-Like Kinase 1
  • Protein Serine-Threonine Kinases / genetics
  • Proto-Oncogene Proteins / genetics
  • RNA, Antisense / administration & dosage*
  • RNA, Antisense / genetics
  • RNA, Antisense / therapeutic use
  • RNA, Guide, CRISPR-Cas Systems

Substances

  • Cell Cycle Proteins
  • Proto-Oncogene Proteins
  • RNA, Antisense
  • DNA
  • Protein Serine-Threonine Kinases